The long-term objectives of this proposal are to elucidate the regulatory mechanism of fatty acid transport and oxidation in the normal and ischemic heart. Plasma long-chain fatty acids are the primary fuel source for energy production in the normal heart. In the ischemic and reperfused myocardium, there is decreased utilization of fatty acids. Furthermore, perfusion with fatty acids results in in situ membrane damage and cardiac dysfunction. Fatty acid-induced injury to ischemic myocardium can be reduced by inhibition of carnitine palmitoyltransferase I (CPTI). Because of its central role in lipid metabolism, CPTI has attracted attention as a potential site for pharmacological intervention in the ischemic heart where elevated levels of acylcarnitines have been associated with arrhythmias; in diabetes mellitus, where fatty acid oxidation is excessive and interferes with glucose oxidation; and in human inherited CPT defects with fatal disturbances in fatty acid oxidation. Therefore, for effective pharmacotherapy of defects in cardiac fatty acid oxidation, it is imperative that we understand the biochemical and molecular mechanisms regulating CPT. The applicant has cloned, sequenced, and expressed human heart CPTI. He now plans to continue these studies with the following specific aims: 1. (a) To map the malonyl CoA and substrate binding sites in human heart CPTI by site-directed mutagenesis and chemical modification studies using residue-specific reagents. (b) To determine the structural basis for the high malonyl CoA sensitivity of human heart CPTI by constructing chimeras between heart and liver CPTI. (2) To prepare milligram quantities of expressed highly purified human heart CPTI and engineered fragments of this enzyme for structural characterization studies. (3) To characterize the promoter region of the gene coding for human heart CPTI, and to study its transcriptional regulation by hormonal, developmental, and dietary factors (a) in cardiac myocytes in vitro and (b) using a transgenic mouse model in vivo.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL052571-07
Application #
6184281
Study Section
Metabolism Study Section (MET)
Project Start
1994-09-01
Project End
2001-07-31
Budget Start
2000-08-01
Budget End
2001-07-31
Support Year
7
Fiscal Year
2000
Total Cost
$197,974
Indirect Cost
Name
Oregon Health and Science University
Department
Biochemistry
Type
Other Domestic Higher Education
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Hostetler, Heather A; Lupas, Dan; Tan, Yingran et al. (2011) Acyl-CoA binding proteins interact with the acyl-CoA binding domain of mitochondrial carnitine palmitoyl transferase I. Mol Cell Biochem 355:135-48
Liu, Hong Yan; Zheng, Guolu; Zhu, Hongfa et al. (2007) Hormonal and nutritional regulation of muscle carnitine palmitoyltransferase I gene expression in vivo. Arch Biochem Biophys 465:437-42
Liu, Hongyan; Zheng, Guolu; Treber, Michelle et al. (2005) Cysteine-scanning mutagenesis of muscle carnitine palmitoyltransferase I reveals a single cysteine residue (Cys-305) is important for catalysis. J Biol Chem 280:4524-31
Relat, Joana; Nicot, Carine; Gacias, Mar et al. (2004) Pig muscle carnitine palmitoyltransferase I (CPTI beta), with low Km for carnitine and low sensitivity to malonyl-CoA inhibition, has kinetic characteristics similar to those of the rat liver (CPTI alpha) enzyme. Biochemistry 43:12686-91
Dai, Jia; Zhu, Hongfa; Woldegiorgis, Gebre (2003) Leucine-764 near the extreme C-terminal end of carnitine palmitoyltransferase I is important for activity. Biochem Biophys Res Commun 301:758-63
Treber, Michelle; Dai, Jia; Woldegiorgis, Gebre (2003) Identification by mutagenesis of conserved arginine and glutamate residues in the C-terminal domain of rat liver carnitine palmitoyltransferase I that are important for catalytic activity and malonyl-CoA sensitivity. J Biol Chem 278:11145-9
Napal, Laura; Dai, Jia; Treber, Michelle et al. (2003) A single amino acid change (substitution of the conserved Glu-590 with alanine) in the C-terminal domain of rat liver carnitine palmitoyltransferase I increases its malonyl-CoA sensitivity close to that observed with the muscle isoform of the enzyme. J Biol Chem 278:34084-9
Zhu, Hongfa; Shi, Jianying; Treber, Michelle et al. (2003) Substitution of glutamate-3, valine-19, leucine-23, and serine-24 with alanine in the N-terminal region of human heart muscle carnitine palmitoyltransferase I abolishes malonyl CoA inhibition and binding. Arch Biochem Biophys 413:67-74
Zheng, Guolu; Dai, Jia; Woldegiorgis, Gebre (2002) Identification by mutagenesis of a conserved glutamate (Glu487) residue important for catalytic activity in rat liver carnitine palmitoyltransferase II. J Biol Chem 277:42219-23
Nicot, Carine; Relat, Joana; Woldegiorgis, Gebre et al. (2002) Pig liver carnitine palmitoyltransferase. Chimera studies show that both the N- and C-terminal regions of the enzyme are important for the unusual high malonyl-CoA sensitivity. J Biol Chem 277:10044-9

Showing the most recent 10 out of 20 publications